Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy
Sponsor: University of Washington
A observational or N/A phase clinical study on HER2-positive Breast Cancer, this trial is ongoing. The trial is conducted by University of Washington and has accumulated 16 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
16 versions recorded-
Nov 2025 — Present [monthly]
Active Not Recruiting
-
Feb 2025 — Nov 2025 [monthly]
Active Not Recruiting
-
Sep 2024 — Feb 2025 [monthly]
Active Not Recruiting
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting
▶ Show 11 earlier versions
-
Jan 2024 — Jul 2024 [monthly]
Active Not Recruiting
-
May 2023 — Jan 2024 [monthly]
Active Not Recruiting
-
Oct 2022 — May 2023 [monthly]
Active Not Recruiting
-
Apr 2022 — Oct 2022 [monthly]
Active Not Recruiting
-
Oct 2021 — Apr 2022 [monthly]
Active Not Recruiting
-
Apr 2021 — Oct 2021 [monthly]
Active Not Recruiting
-
Jan 2021 — Apr 2021 [monthly]
Active Not Recruiting
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting
Status: Enrolling By Invitation → Active Not Recruiting
-
Feb 2020 — Oct 2020 [monthly]
Enrolling By Invitation
-
Dec 2019 — Feb 2020 [monthly]
Enrolling By Invitation
-
Dec 2018 — Dec 2019 [monthly]
Enrolling By Invitation
First recorded
Aug 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Washington
For direct contact, visit the study record on ClinicalTrials.gov .